SMPD1 and glioblastoma: Paradoxically, Gramatzki et al. detected opposite results several years later with a different chemotherapeutic, demonstrating that the overexpression of aSMase did not sensitize glioblastoma cells to radiation or chemotherapy with temozolomide, the current chemotherapeutic considered as standard (110).